Evidence map›Paper›PMID 33215525›Full record

ReviewFuture microbiology2020

The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic.

Lígia N de M Ribeiro, Belchiolina B Fonseca

Abstract readReview
In one paragraph

Review in Future microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lígia N de M RibeiroSchool of Veterinary Medicine, Federal University of Uberlandia, Uberlândia, Brazil.ORCID 0000-0001-6097-5449
Belchiolina B FonsecaSchool of Veterinary Medicine, Federal University of Uberlandia, Uberlândia, Brazil.ORCID 0000-0001-8485-078X

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.336865/2019-00
6 · The paper itself

Abstract

There is no effective therapy against COVID-19 available so far. In the last months, different drugs have been tested as potential treatments for COVID-19, exhibiting high toxicity and low efficacy. Therefore, nanotechnology can be applied to improve the therapeutic action and minimize the toxicity of loaded drugs. In this review, we summarized the drugs tested as COVID-19 treatment and the advantages of antiviral nanostructured drug-delivery systems. Such systems have demonstrated low

Indexed as

COVID-19 Drug TreatmentDrug Delivery SystemsAnimalsAntiviral AgentsClinical Trials as TopicDrug CompoundingHumansMiceMiddle East Respiratory Syndrome CoronavirusNanostructuresNanotechnologySARS-CoV-2Severe acute respiratory syndrome-related coronavirusAntiviral AgentsCOVID-19drug toxicitynanostructured delivery systemsnanotechnology

Identifiers

PMID33215525
PMCPMC7682556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.